secwatch / observer

8-K filed May 29, 2026, 5:11 PM ET ticker CRDF CIK 0001213037

litigation confidence high sentiment negative materiality 0.90

NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination

Cardiff Oncology, Inc.

NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.
NMS claims Cardiff failed to correct inventorship to include Dr. Barbara Valsasina on two U.S. patents and failed to use commercially reasonable efforts for onvansertib.
Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and declaratory judgment that it did not breach the agreement.
Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.
Dispute centers on rights to onvansertib, a key pipeline asset; potential impact on development timeline.

Featured in Daily 8-K Digest

Selected #7 for 2026-05-29. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-248711
form_type: 8-K
ticker: CRDF
cik: 0001213037
company_name: Cardiff Oncology, Inc.
filed_at: 2026-05-29T21:11:12+00:00
discovered_at: 2026-05-29T21:12:00.208107+00:00
generated_at: 2026-05-29T21:12:30.664325+00:00
sec_items: ["1.01"]
event_type: litigation
sentiment: negative
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-248711
json_url: https://secwatch.observer/filing/0001193125-26-248711.json
markdown_url: https://secwatch.observer/filing/0001193125-26-248711.md
text_url: https://secwatch.observer/filing/0001193125-26-248711.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/0001193125-26-248711-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/crdf-20260527.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

NMHI

Nature's Miracle settles noteholder litigation for $575K; must reserve 222M shares

Nature's Miracle Holding Inc. May 27, 2026, 8:14 PM ET litigation Items 1.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

OPY

Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings

OPPENHEIMER HOLDINGS INC April 27, 2026, 7:59 PM ET litigation Items 1.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

AGAE

Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment

Allied Gaming & Entertainment Inc. April 21, 2026, 7:59 PM ET litigation Items 1.01, 5.02, 8.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

TRNR

TRNR recovers $6.4M in full settlement of Sportstech loan dispute, ends legal proceedings

Interactive Strength, Inc. March 5, 2026, 6:59 PM ET litigation Items 1.01, 8.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

MRNA

Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent

Moderna, Inc. March 5, 2026, 6:59 PM ET litigation Items 1.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

ROIV

Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent

Roivant Sciences Ltd. March 3, 2026, 6:59 PM ET litigation Items 1.01, 7.01, 8.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

ABUS

Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026

Arbutus Biopharma Corp March 3, 2026, 6:59 PM ET litigation Items 1.01, 8.01, 9.01

same SEC item: 1.01 same event type: litigation similar materiality

Filing page SEC filing

OTTR

Otter Tail settles two class claims in PVC pipe antitrust litigation for $73.5M

Otter Tail Corp May 29, 2026, 10:47 AM ET litigation Items 1.01

same SEC item: 1.01 same event type: litigation

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-248711

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.